Loading...

Merck & Co., Inc.

MRKNYSE
HealthcareDrug Manufacturers - General
$76.82
$0.42(0.55%)

Merck & Co., Inc. (MRK) Stock Overview

Explore Merck & Co., Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
6.74%
6.74%
Profit Growth
$6.89
4589.59%
EPS Growth
$6.89
4714.29%
Operating Margin
35.78%
668.18%
ROE
38.16%
4589.59%
Dividend Yield
0.00%
8.05%

Analyst Recommendations

Strong Buy
0
Buy
4
Hold
5
Sell
0
Strong Sell
0

Price Targets

Low$82.00
Average$130.18
High$148.00

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

CEO

Mr. Robert M. Davis J.D.

Employees

73,000

Headquarters

2000 Galloping Hill Road, Rahway, NJ

Founded

1978

Frequently Asked Questions